Patents by Inventor Inger Brock

Inger Brock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7838013
    Abstract: The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: November 23, 2010
    Assignee: Statens Serum Institut
    Inventors: Peter Andersen, Inger Brock, Karin Weldingh
  • Publication number: 20060115847
    Abstract: The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. Tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria. Four recently characterized proteins with this diagnostic potential were selected.
    Type: Application
    Filed: November 8, 2005
    Publication date: June 1, 2006
    Inventors: Peter Andersen, Inger Brock, Karin Weldingh
  • Publication number: 20040013685
    Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptide.
    Type: Application
    Filed: June 1, 2001
    Publication date: January 22, 2004
    Inventors: Peter Andersen, Rikke Louise Vinther Skjot, Li Mei Meng Okkels, Inger Brock, Thomas Oettinger